论文部分内容阅读
胶质瘤是常见的中枢神经系统肿瘤,其恶性程度高且总体预后较差。传统的基于组织形态学的病理分型已经不能满足临床中对胶质瘤预后判断及治疗的需要。近年来开展的胶质瘤相关的遗传学研究使得许多遗传学分子标志物被发现并逐步应用于临床。遗传学分子标志物在胶质瘤的预后判断及胶质瘤患者的治疗指导方面有很高的应用价值,同时为胶质瘤的治疗相关研究提供新的方向。全文就影响胶质瘤患者预后的遗传学分子标志物的研究进展进行综述。
Glioma is a common central nervous system tumor with a high degree of malignancy and poor overall prognosis. The traditional histopathology-based pathological typing can not meet the clinical needs of the prognosis and treatment of glioma. In recent years, glioma-related genetic studies have led to many genetic molecular markers have been found and gradually applied to clinical. Genetics molecular markers in the prognosis of glioma and glioma patients with therapeutic guidance has a high value, and for the treatment of glioma related research provides a new direction. The article reviews the progress of genetic molecular markers that affect the prognosis of glioma patients.